Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study
Chiglitazar is particularly effective for participants with pronounced dawn phenomenon, semaglutide excels in lipid metabolism improvement and kidney protection, while pioglitazone remains effective for insulin resistance and glycemic control. These findings provide evidence-based guidance for individualized T2D management.
Authors
- Chuanfeng Liu (ORCID: https://orcid.org/0000-0002-6549-2013)
- Yongzhuo Yu (ORCID: https://orcid.org/0009-0008-5412-5059)
- Wenxuan Li
- Bingzi Dong (ORCID: https://orcid.org/0000-0003-2446-0725)
- Yangang Wang (ORCID: https://orcid.org/0000-0001-6597-420X)
- Lili Xu (ORCID: https://orcid.org/0000-0001-8759-1568)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1007/s13300-025-01724-9
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29